Parthenogen holds full rights on a PCT patent for an innovative drug product intended for the treatment of human infertility. The patent is already approved in Europe (PCT/EP2012/060122 – 15/15 claims approved) whereas the procedures for the USA approval are still ongoing.
The project was so far entirely managed in-house. Although it is a low demanding project, any further development largely exceeds the current investment and operative capability of the company, accordingly we are seeking partners willing to invest.
Parthenogen is open to any proposal allowing the project to reach the market for the benefit of the patients: we are definitely convinced that this new treatment strategy has the potential to significantly improve the clinical gain from Controlled Ovarian Hyperstimulation intended for Assisted Reproduction Technologies. Thus, we would be happy for any funds conferred to the company to develop the project with the support of our internal expertise in the field in exchange for a very generous participation to the revenues. In alternative, we are ready to fully release the project, also in front of a very limited compensation, to anybody ensuring a serious interest to progress with the development.